Surgical treamtent of giant gastrointestinal mesenchymal tumor after neoadjuvant therapy: a case report and review of the literature

doi:10.3877/cma.j.issn.1674-0785.2023.03.022

Abstract

Abstract:

Objective

To report a case of giant gastrointestinal mesenchymal tumor treated by surgical resection after neoadjuvant therapy, and to investigate the optimal timing of surgery for giant gastrointestinal mesenchymal tumor preoperatively treated with imatinib mesylate by reviewing the relevant literature.

Methods

A case of giant gastrointestinal mesenchymal tumor is reported and the relevant literature is reviewed.

Results

A 47-year-old woman presented with abdominal mass, abdominal pain, and abdominal distension, and she was diagnosed as having malignant gastrointestinal malignant mesenchymal tumor by CT and puncture biopsy. The maximum diameter of the tumor was about 233 mm × 117 mm × 213 mm at the initial diagnosis. No recurrence of metastasis was observed in the postoperative follow-up to date.

Conclusion

For patients with initially unresectable giant gastrointestinal mesenchymal tumor, surgery can be chosen when the maximum benefit of molecular targeted drug therapy is achieved to improve the R0 resection rate.

Key words: Giant gastrointestinal mesenchymal tumor, MDT discussion, Neoadjuvant therapy, Literature review

Fei Kong, Fabing Tang, Qiong Wei, Shanlin Fan, Wenzhen Yuan. Surgical treamtent of giant gastrointestinal mesenchymal tumor after neoadjuvant therapy: a case report and review of the literature[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(03): 360-363.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2023.03.022

https://zhlcyszz.cma-cmc.com.cn/EN/Y2023/V17/I03/360

Figures/Tables 3

References 27

1	Blay JY, Kang YK, Nishida T, et al. Gastrointestinal stromal tumours [J]. Nat Rev Dis Primers, 2021, 7(1): 22.
2	Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas [J]. Annu Rev Pathol, 2008, 3: 557-586.
3	Huss S, Pasternack H, Ihle MA, et al. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events [J]. Hum Pathol, 2017, 62: 206-214.
4	曹晖, 高志冬, 何裕隆, 等. 胃肠间质瘤规范化外科治疗中国专家共识(2018版) [J]. 中国实用外科杂志, 2018, 38(9): 965-973.
5	沈琳, 曹晖, 秦叔逵, 等. 中国胃肠间质瘤诊断治疗共识(2017年版) [J]. 肿瘤综合治疗电子杂志, 2018, 4(1): 31-43.
6	Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J]. Lancet, 2009, 373(9669): 1097-1104.
7	Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial [J]. JAMA, 2012, 307(12): 1265-1272.
8	陶凯雄, 张鹏, 李健, 等. 胃肠间质瘤全程化管理中国专家共识(2020版) [J]. 中国实用外科杂志, 2020, 40(10): 1109-1119.
9	Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology [J]. Nat Rev Cancer, 2011, 11(12): 865-878.
10	岳松伟, 高剑波, 杨学华, 等. 胃间质瘤的螺旋CT诊断价值 [J]. 中国医学影像技术, 2006(7): 1035-1038.
11	Heron M. Deaths: Leading Causes for 2011 [J]. Natl Vital Stat Rep, 2015, 64(7): 1-96.
12	Voltaggio L, Murray R, Lasota J, et al. Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature [J]. Hum Pathol, 2012, 43(5): 650-659.
13	Goldfarb LG, Vicart P, Goebel HH, et al. Desmin myopathy [J]. Brain, 2004, 127(Pt 4): 723-734.
14	Wang WJ, Li HT, Yu JP, et al. Identification of key genes and associated pathways in KIT/PDGFRA wild-type gastrointestinal stromal tumors through bioinformatics analysis [J]. Mol Med Rep, 2018, 18(5): 4499-4515.
15	陈净慈, 吴焕文, 陆俊良, 等. 胃肠道间质瘤c-KIT, PDGFRA基因突变及CD117, DOG-1蛋白的表达情况 [J]. 临床与病理杂志, 2018, 38(2): 10.
16	韩振宇, 郑吉阳, 周威, 等. 胃肠道间质瘤基因突变及靶向治疗进展 [J]. 西南国防医药, 2018, 28(6): 599-601.
17	von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2022, 20(7): 815-833.
18	Joyon N, Dumortier J, Aline-Fardin A, et al. Gastrointestinal stromal tumors (GIST) presenting in the liver: Diagnostic, prognostic and therapeutic issues [J]. Clin Res Hepatol Gastroenterol, 2018, 42(2): e23-e28.
19	Raitio A, Salim A, Mullassery D, et al. Current treatment and outcomes of pediatric gastrointestinal stromal tumors (GIST): a systematic review of published studies [J]. Pediatr Surg Int, 2021, 37(9): 1161-1165.
20	von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(5): 536-563.
21	Bednarski BK, Araujo DM, Yi M, et al. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors [J]. Ann Surg Oncol, 2014, 21(8): 2499-2505.
22	Casali PG, Blay JY, Abecassis N, et al. Electronic address: clinicalguidelines@esmo.org. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2022, 33(1): 20-33.
23	Ishikawa T, Kanda T, Kameyama H, et al. Neoadjuvant therapy for gastrointestinal stromal tumor [J]. Transl Gastroenterol Hepatol, 2018, 3: 3.
24	Raut CP, Ashley SW. How I do it: surgical management of gastrointestinal stromal tumors [J]. J Gastrointest Surg, 2008, 12(9): 1592-1599.
25	DeMatteo RP. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery? [J]. Ann Surg Oncol, 2007, 14(1): 1-2.
26	Saied GM, Kensarah AM. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients [J]. Int J Surg, 2010, 8(2): 105-108.
27	陶凯雄, 王坚, 张鹏, 等. 胃肠间质瘤基因检测与临床应用的中国专家共识(2021版) [J]. 临床肿瘤学杂志, 2021, 26(10): 920-927.

[1]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[2]	Yaping Wang, Jing Fan, Niuniu Hou, Rui Ling. Clinical significance of tumor-infiltrating lymphocytes in HER-2-positive early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 203-209.
[3]	Jianxin Lyu, Yueyun Zhu, Ya’nan Zhang, Haolin Hu, Baocai Wang, Xinhua Cao, Lifei Han, Xiao Ma. Efficacy comparison of two neoadjuvant chemotherapy regimens in human epidermal growth factor receptor 2 positive breast cancer: a retrospective study [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(02): 88-92.
[4]	Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[5]	Xiong Li, Yongkuan Cao. Clinical study of ISR with different distal incisal margin distances after neoadjuvant therapy for locally advanced rectal [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 443-446.
[6]	Longfei Peng, Xin Wang, Dian Xia, Songbai Yan, Jinyou Wang, Liangkuan Bi. Preliminary experiences of laparoscopic extraperitoneal radical cystectomy with orthotopic ileal neobladder [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(01): 7-10.
[7]	Chunyan Li, Jiancheng Xu, Yue Zhang, Jing Xu, Mingdong Hu. Pulmonary sarcomatoid carcinoma: a case report and review of the literature [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 195-199.
[8]	Nini Wang, Rongrong Chen, Qing Zhang, Chengshi Zhang, Donghui Cui, Jian Wu, Han Lei, Yunfeng Zhao. Primary mucinous adenocarcinoma of the lung: three cases report and literature review [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 190-194.
[9]	Chuanchao He, Zhiyu Xiao. Comprehensive treatment mode and strategy for advanced hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 486-489.
[10]	Min Zou, Ming Xu, Weiqiang Wu, Mingbin Gui, Feng Gao. Focus of neoadjuvant radiotherapy and chemotherapy for low rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 363-371.
[11]	Xinyu Shi, Jinbing Sun, Songbing He. Progress of blood biomarkers in neoadjuvant chemoradiotherapy of rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(03): 228-233.
[12]	Zheng Dai, Jiahao Dai, Xiangnan Yu, Zheng Wang, Guobin Wang. Progress in colorectal minimally invasive surgical procedures, equipments and strategies [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 158-162.
[13]	Zhongyuan Bai, Wei Zhang, Yongliang Feng, Wenqi Bai, Lingmin Li. Pathological complete response and predictive factors analysis of rectal cancer after neoadjuvant therapy [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(01): 50-55.
[14]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[15]	Xuefen Chen, Jingmin Deng. Literature review of 179 cases of primary pulmonary lymphoepithelioma-like carcinoma in the last 30 years [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 551-556.

Please choose a citation manager

Content to export